PRGO - Your Daily Scoop: Five Prime Progresses Endocyte's rPFS And Stock Offering Tracon's Results Published
Stocks in News: FPRX, ECYT
Five Prime launches late-stage study of bemarituzumab + chemo in gastric cancer or GEJ
Discussion: Five Prime Therapeutics' (FPRX) FPA144 (bemarituzumab) plus chemotherapy completed Part 1 of a Phase 1/3 clinical trial evaluating treatment-naive patients with advanced gastric cancer ((GC)) or cancer of the gastroesophageal junction ((GEJ)). The trial now moves to its subsequent parts in Phase 3. Overall survival ((OS)) is the primary endpoint of the trial. Progression-free survival ((PFS)) and objective response rate ((ORR)) are the secondary endpoints.
Approximately 10% of the cases of gastric